YS Biopharma Company Insiders

YS Stock   0.85  0.04  4.49%   
YS Biopharma employs about 754 people. The company is managed by 8 executives with a total tenure of roughly 1760 years, averaging almost 220.0 years of service per executive, having 94.25 employees per reported executive. Breaking down YS Biopharma's management performance can provide insight into the firm performance.
  
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in YS Biopharma Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

YS Biopharma Management Team Effectiveness

The company has Return on Asset (ROA) of (0.1206) % which means that for every 100 dollars spent on asset, it generated a loss of $0.1206. This is way below average. Likewise, it shows a return on total equity (ROE) of (0.6169) %, which implies that it produced no returns to current stockholders. YS Biopharma's management efficiency ratios could be used to measure how well YS Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.08 in 2024. Return On Capital Employed is likely to gain to -0.12 in 2024. At this time, YS Biopharma's Non Currrent Assets Other are comparatively stable compared to the past year. Intangibles To Total Assets is likely to gain to 0.06 in 2024, whereas Total Assets are likely to drop slightly above 1.6 B in 2024.
Common Stock Shares Outstanding is likely to drop to about 101.7 M in 2024

YS Biopharma Workforce Comparison

YS Biopharma Co is rated first in number of employees category among related companies. The total workforce of Health Care industry is at this time estimated at about 927. YS Biopharma totals roughly 754 in number of employees claiming about 81% of equities under Health Care industry.

YS Biopharma Profit Margins

The company has Net Profit Margin (PM) of (0.67) %, which may indicate that it does not properly execute on its own pricing strategies. This is way below average. Likewise, it shows Net Operating Margin (NOM) of (1.17) %, which signifies that for every 100 dollars of sales, it has a net operating loss of $1.17.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.620.7
Fairly Down
Slightly volatile

YS Biopharma Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. YS Biopharma Price Series Summation is a cross summation of YS Biopharma price series and its benchmark/peer.

YS Biopharma Notable Stakeholders

A YS Biopharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as YS Biopharma often face trade-offs trying to please all of them. YS Biopharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting YS Biopharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Hui ShaoCEO PresidentProfile
Nan ZhangCEO DirectorProfile
Chunyuan CPAChief DirectorProfile
Yuan LiuDirector ResearchProfile
Chunyuan WuChief DirectorProfile
Zenaida MojaresChief OfficerProfile
Gang LiHead SalesProfile
Hongman JiaChief OfficerProfile

About YS Biopharma Management Performance

The success or failure of an entity such as YS Biopharma often depends on how effective the management is. YS Biopharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of YS Biopharma management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the YS Biopharma management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.08)(0.08)
Return On Capital Employed(0.13)(0.12)
Return On Assets(0.08)(0.08)
Return On Equity(0.23)(0.22)
The data published in YS Biopharma's official financial statements usually reflect YS Biopharma's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of YS Biopharma. For example, before you start analyzing numbers published by YS Biopharma accountants, it's critical to develop an understanding of what YS Biopharma's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of YS Biopharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, YS Biopharma's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in YS Biopharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of YS Biopharma Co. Please utilize our Beneish M Score to check the likelihood of YS Biopharma's management manipulating its earnings.

YS Biopharma Workforce Analysis

Traditionally, organizations such as YS Biopharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare YS Biopharma within its industry.

YS Biopharma Manpower Efficiency

Return on YS Biopharma Manpower

Revenue Per Employee911.4K
Revenue Per Executive85.9M
Net Loss Per Employee192.9K
Net Loss Per Executive18.2M
Working Capital Per Employee500.3K
Working Capital Per Executive47.2M
When determining whether YS Biopharma is a strong investment it is important to analyze YS Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact YS Biopharma's future performance. For an informed investment choice regarding YS Biopharma Stock, refer to the following important reports:
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in YS Biopharma Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Complementary Tools for YS Biopharma Stock analysis

When running YS Biopharma's price analysis, check to measure YS Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy YS Biopharma is operating at the current time. Most of YS Biopharma's value examination focuses on studying past and present price action to predict the probability of YS Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move YS Biopharma's price. Additionally, you may evaluate how the addition of YS Biopharma to your portfolios can decrease your overall portfolio volatility.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Commodity Directory
Find actively traded commodities issued by global exchanges
Is YS Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of YS Biopharma. If investors know YS Biopharma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about YS Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.56)
Revenue Per Share
5.159
Quarterly Revenue Growth
(0.50)
Return On Assets
(0.12)
Return On Equity
(0.62)
The market value of YS Biopharma is measured differently than its book value, which is the value of YS Biopharma that is recorded on the company's balance sheet. Investors also form their own opinion of YS Biopharma's value that differs from its market value or its book value, called intrinsic value, which is YS Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because YS Biopharma's market value can be influenced by many factors that don't directly affect YS Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between YS Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if YS Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, YS Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.